NMRA Q3 2025 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$5M

Operating Income

-$58M

Net Income

-$57M

EPS (Diluted)

$-0.35

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$178M

Total Liabilities

$46M

Stockholders' Equity

$132M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$5M	$0	—
Operating Income	-$58M	-$77M	+24.7%
Net Income	-$57M	-$73M	+21.8%